We conducted a retrospective chart review of treatm ent outcomes in 17 adults who had been selected to undergo concomitant chemotherapy and radiation (chemoIXRT) f or late-stage oropharynge al cancers. All patients had been treated at the West Los Angeles VA Medical Center between Mar ch 1,1998, and Sept. 30,2000. Nine patients had a primary tumor at the base ofthe tongue, five had a primary tumor in the tonsillar area, and three had a tumor that affected both sites. Of this group, 15 pat ients completed one to three cycles ofchemolXRT, and the remaining two died during therapy. At the most recentfo llow-up, 9 of the 17 patients (52.9 %) were documented to still be alive; seven patients had earlier died as a result of their primary tumor or a distant metastasis, and one patient had been lost to follow-up after completing treatm ent. At study 's end, the duration of post-treatment survival ranged from 2 to 36 months (mean: 12.5). Based on the results of our small series, we conclude that chemolXRT is a valid alternati ve to surgery with postoperative radiation and to radiation alone. ChemolXRT yields acceptable rates of local control and allows fo r organ preservation with tolerable side effec ts.
Introduction
Some 30% of head and neck cancers occur in the oroph arynx, and otolaryngologists diagnose more than 30,000 such cases each year.' In the past, patient s with oropharyngeal cancers have been classified into two general categories: those who are surgically salvageable and those who are not. The standard treatment" for patients whose cancers are surgically resectable includes radiotherapy in. addition to surgery.' Th ose who cannot be operated on are generally treated with radiation alone.
Because surgery can lead to significa nt morbidity and loss of organ function, there is a need for an alternate treatment.' In this article, we describe our study of the effect of concomitant chemotherapy and radiation (chemo/ XRT) on surviv al in patients with advanced oropharyngeal cancers. We also discuss outcomes in terms of morbidity and preservation of organ function.
Patients and methods
We perform ed a retrospecti ve chart review of 17 patients who had been chosen to undergo chemo/XRT for the treatment of advanced-stage oroph aryngeal cancers at the West Los Angele s VA Medical Cente r between March I, 1998, and Sept. 30, 2000 . These patients had been diagnosed on the basis of physical examination, panendo scopy, and advanced imaging studies (computed tomography and magnetic resonance imaging). All patients had been staged in accordance with the current recommendations of the American Joint Committee on Cancer (AJCC). 4 Prior to treatment , each case was discussed at a meetin g of a multidisciplinary head and neck tumor panel, and all patients underwent a dental evaluatio n.
The reaso ns that patients had been offered chemo/XRT rather than surgery with postoperative radiation were varied. Some patient s were deemed to have unresectable tumors, some were poor surgical candidates because of their overall medical condit ion, and one had refused to undergo surgery. The criteria for establishing disease as unresectable were (I ) an invasion of a tumor into the prevertebral fascia or skull base, (2) tumor fixation to the carotid artery, and (3) the presence of a distant metasta sis.
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Discussion
The success of chemo/XRT protocols for organ preservation in patients with laryngeal cancers has led to an increase in the use of these protocols for nonlaryngeal head and neck squamous cell disease. Many previous studies have addressed the use of chemolXRT for both laryngeal and nonlaryngeal squamous cell cancers, but the use of chemolXRT as a definitive treatment specifically for advanced oropharyngeal cancers has not been well studied.
Many variables must be taken into consideration in reviewing the results of treatment for oropharyngeal cancers . Cancers at different sites in the oropharynx (i.e., the tonsils and the base of the tongue) can respond differently to treatment. The response to treatment of cervical metastases is also different from the response of primary tumors . Because our current staging system reflects a combination of T and N stages, it is often difficult to beam boosts were delivered to selected nodal regions. The total number of treatments delivered to individual patients ranged from 7 to 40 . Daily radiation was delivered in a single 200-cOy dose ; the mean total tumor dose delivered over a 6-to 7-week period was 6,197 cOy.
Survival. Responses to chemo/XRT varied , and at study's end , survival times ranged from 2 to 36 months (mean: 12.5). At the most recent follow-up, 9 of the 17 patients (52.9 %) were documented to still be alive. Among the others, 1 patient who survived chemo/XRT was lost to follow-up; 5 patients died following treatment as a result of either their primary tumor or a metastasis to the lung, bone, or liver; and 2 others died during treatment.
Organ preservation. Among the 17 patients, oropharyngeal function was preserved in all 12 (70.6 %) who survived the full course of treatment.
Morbidity. The most common side effects of treatment were stomatitis and dysphagia!odynophagia (table 2 ). In addition, five patients required a gastrostomy tube during chemo/XRT. One patient required a tracheostomy tube placement for respiratory distress during treatment, and he died shortly thereafter. determine whether treatment protocols for advancedstage cancers are effective specifically for primary sites or nodal metastases.
In a series of patients with cancer of the base of the tongue, Gourin and Johnson found that overall control rates following surgery with postoperative radiation ranged from 72 to 92 %. 5 In a study of patients with oropharyngeal cancers, Zelefsky et al reported an overa1l7-year survival rate of 52 % and a disease-free control rate of 64%.6 In patients with stage IV cancers of the head and neck following chemo/XRT, Vokes et al found that the locoregional control rate was 92% and overall survival was 55% (median follow-up: 38 mo).' Calais et al reported a 3-year survival rate of 42% among patients with oropharyngeal cancers in the chemo/XRT arm of their study." Nathu et al found a 63% local control rate for oropharyngeal cancers after 5 years." Poole et al demonstrated local control rates of 71 and 60% in primary oropharyngeal tumors and cervical node metastases, respectively.'?
In our small study of patients with stage II to IV cancers of the oropharynx, the initial local and regional control rate was 88%. At 12 months, our local control rate dropped to 70%, and at 24 month s, it was less than 60 %. These rates are consistent with those reported in earlier studies of chemolXRT and in studies of surgery with postoperative radiation.
The morbidity experienced by patients who undergo surgery with postoperative radiation is significantly different from that experienced by patients who undergo chemo/XRT. The side effects of surgery with postoperative radiation can significantly compromise quality of life. These side effects can be categorized as early and late morbidities. Early morbidities are often related to the surgery itself, and they include nerve deficits, flap failures, early and delayed wound infections, and complications of anesthesia. Late morbidities include strictures and osteoradionecrosis. Surgery can also complicate the detection of recurrences. II Side effects of postoperative radiation include severe stomatitis, xerostomia, and malnutrition serious enough to nece ssitate the placement of a gastro stomy tube. Moreover, surgery with postoperative radiation can also compromise organ function. Patients who undergo resection of a stage IV lesion of the tonsil or base of the tonguefrequently experience numerous problems in their attempts to carry on normal activities of daily living . Such problems include inabilities to speak intelligibly, to chew and maintain a regular diet, and to eat in public without embarrassment.
The most common early complications associated with cheni.o/XRT in our study were stomatitis, dysphagia! odynophagia, and the need for gastrostomy tube place-Volume 82, Number 5 369 LOTEMPIO. WANG, SADEGHI ment. The extent of these morbidities had decreased greatly by the 12-and 24-month follows -ups. Our data suggest that patients with advanced-stage oropharyngeal cancers should be offered the option of being treated with chemo/XRT. In our small series, locoregional control rates following chemo/XRT were similar to those that have been reported following surgery with postoperative radiation. In addition , organ preservation was achieved with an acceptable degree of morbidity .
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